Insider Trading Alert - MTDR, ABCO And CTIC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Aug. 15, 2014, 95 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $116.62 to $15,679,644.00.

Highlighted Stocks Traded by Insiders:

Matador Resources (MTDR) - FREE Research Report

Sepulveda Carlos M, who is Director at Matador Resources, bought 1,000 shares at $25.09 on Aug. 15, 2014. Following this transaction, the Director owned 297,459 shares meaning that the stake was boosted by 0.34% with the 1,000-share transaction.

The shares most recently traded at $26.00, up $0.91, or 3.5% since the insider transaction. Historical insider transactions for Matador Resources go as follows:

  • 4-Week # shares bought: 4,000
  • 12-Week # shares bought: 16,000
  • 24-Week # shares bought: 16,000

The average volume for Matador Resources has been 1.0 million shares per day over the past 30 days. Matador Resources has a market cap of $1.8 billion and is part of the basic materials sector and energy industry. Shares are up 34.71% year-to-date as of the close of trading on Friday.

Matador Resources Company, an independent energy company, acquires, explores, develops, and produces oil and natural gas resources in the United States. The company has a P/E ratio of 22.6. Currently, there are 6 analysts who rate Matador Resources a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MTDR - FREE

TheStreet Quant Ratings rates Matador Resources as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Matador Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Advisory Board (ABCO) - FREE Research Report

Van Hoose Mary, who is Chief Talent Officer at Advisory Board, sold 1,333 shares at $50.76 on Aug. 15, 2014. Following this transaction, the Chief Talent Officer owned 26,885 shares meaning that the stake was reduced by 4.72% with the 1,333-share transaction.

The shares most recently traded at $49.57, down $1.19, or 2.4% since the insider transaction. Historical insider transactions for Advisory Board go as follows:

  • 4-Week # shares sold: 1,333
  • 12-Week # shares sold: 2,666
  • 24-Week # shares sold: 15,999

The average volume for Advisory Board has been 249,300 shares per day over the past 30 days. Advisory Board has a market cap of $1.8 billion and is part of the services sector and diversified services industry. Shares are down 20.89% year-to-date as of the close of trading on Friday.

The Advisory Board Company provides best practices research and analysis, business intelligence and performance technology software, and consulting and management services to the health care and education industries in the United States and internationally. The company has a P/E ratio of 104.9. Currently, there are 10 analysts who rate Advisory Board a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ABCO - FREE

TheStreet Quant Ratings rates Advisory Board as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full Advisory Board Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cell Therapeutics (CTIC) - FREE Research Report

Bianco James A, who is President and CEO at Cell Therapeutics, sold 40,000 shares at $2.54 on Aug. 15, 2014. Following this transaction, the President and CEO owned 2.3 million shares meaning that the stake was reduced by 1.74% with the 40,000-share transaction.

The shares most recently traded at $3.01, up $0.47, or 15.51% since the insider transaction. Historical insider transactions for Cell Therapeutics go as follows:

  • 4-Week # shares sold: 12,000
  • 12-Week # shares sold: 161,000
  • 24-Week # shares sold: 1.2 million

The average volume for Cell Therapeutics has been 3.7 million shares per day over the past 30 days. Cell Therapeutics has a market cap of $440.5 million and is part of the health care sector and drugs industry. Shares are up 53.93% year-to-date as of the close of trading on Tuesday.

CTI BioPharma Corp., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer.

Exclusive Offer: Get the latest Stock Analysis on CTIC - FREE

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Dow Logs Eighth Straight Drop as Stocks Slump

Dow Logs Eighth Straight Drop as Stocks Slump

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

This Is What's Hot Thursday - Stocks Slide, Intel's CEO Woes & Major Movers

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Banks Pass Fed 'Stress Test' With Room for Dividends, Buybacks

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

U.S. Drillers at Mercy of Iran, Saudi Production Spat as OPEC Meeting Begins

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?

Comcast's Brian Roberts vs. Disney's Bob Iger: Which Titan Will Nab Fox?